PharmX Technologies (ASX:PHX) Piotroski F-Score: 4 (As of Jun. 26, 2026) — 20% Below Median


ASX:PHX PharmX Technologies Ltd ASX:PHX
40 GF Score
Price A$0.13
GF Value A$0.07
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is PharmX Technologies Piotroski F-Score?

PharmX Technologies ASX:PHX 40 Piotroski F-Score is 4 as of Jun. 26, 2026, which is 20% below its 10-year median of 5.00. GuruFocus rates ASX:PHX with a GF Score™ of 40/100 and a GF Value™ of A$0.07 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 652 Healthcare Providers & Services companies, PharmX Technologies ranks worse than 67.33% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

PharmX Technologies has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for PharmX Technologies's Piotroski F-Score or its related term are showing as below:

ASX:PHX' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 5   Max: 7
Current: 4

During the past 13 years, the highest Piotroski F-Score of PharmX Technologies was 7. The lowest was 3. And the median was 5.

PharmX Technologies  (ASX:PHX) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


PharmX Technologies Piotroski F-Score Related Terms


PharmX Technologies Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for PharmX Technologies's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PharmX Technologies Piotroski F-Score Chart

PharmX Technologies Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.00 7.00 4.00 3.00 4.00

PharmX Technologies Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 3.00 0.00 4.00 0.00

ASX:PHX vs VEEV, BTSG, TEM: Piotroski F-Score Comparison

For the Health Information Services subindustry, PharmX Technologies's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PharmX Technologies Piotroski F-Score vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, PharmX Technologies's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where PharmX Technologies's Piotroski F-Score falls into.


ASX:PHX
40GF Score
PharmX Technologies Ltd ASX:PHX
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun25) TTM:Last Year (Jun24) TTM:
Net Income was A$-0.26 Mil.
Cash Flow from Operations was A$-8.13 Mil.
Revenue was A$7.32 Mil.
Gross Profit was A$5.96 Mil.
Average Total Assets from the begining of this year (Jun24)
to the end of this year (Jun25) was (29.857 + 18.825) / 2 = A$24.341 Mil.
Total Assets at the begining of this year (Jun24) was A$29.86 Mil.
Long-Term Debt & Capital Lease Obligation was A$0.54 Mil.
Total Current Assets was A$5.76 Mil.
Total Current Liabilities was A$1.73 Mil.
Net Income was A$-1.77 Mil.

Revenue was A$6.49 Mil.
Gross Profit was A$5.25 Mil.
Average Total Assets from the begining of last year (Jun23)
to the end of last year (Jun24) was (36.52 + 29.857) / 2 = A$33.1885 Mil.
Total Assets at the begining of last year (Jun23) was A$36.52 Mil.
Long-Term Debt & Capital Lease Obligation was A$0.13 Mil.
Total Current Assets was A$16.37 Mil.
Total Current Liabilities was A$11.95 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

PharmX Technologies's current Net Income (TTM) was -0.26. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

PharmX Technologies's current Cash Flow from Operations (TTM) was -8.13. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Jun24)
=-0.264/29.857
=-0.00884215

ROA (Last Year)=Net Income/Total Assets (Jun23)
=-1.769/36.52
=-0.04843921

PharmX Technologies's return on assets of this year was -0.00884215. PharmX Technologies's return on assets of last year was -0.04843921. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

PharmX Technologies's current Net Income (TTM) was -0.26. PharmX Technologies's current Cash Flow from Operations (TTM) was -8.13. ==> -8.13 <= -0.26 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Jun25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun24 to Jun25
=0.54/24.341
=0.02218479

Gearing (Last Year: Jun24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun23 to Jun24
=0.133/33.1885
=0.00400741

PharmX Technologies's gearing of this year was 0.02218479. PharmX Technologies's gearing of last year was 0.00400741. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Jun25)=Total Current Assets/Total Current Liabilities
=5.758/1.73
=3.3283237

Current Ratio (Last Year: Jun24)=Total Current Assets/Total Current Liabilities
=16.369/11.95
=1.36979079

PharmX Technologies's current ratio of this year was 3.3283237. PharmX Technologies's current ratio of last year was 1.36979079. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

PharmX Technologies's number of shares in issue this year was 598.507. PharmX Technologies's number of shares in issue last year was 598.178. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=5.961/7.32
=0.81434426

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=5.253/6.487
=0.80977339

PharmX Technologies's gross margin of this year was 0.81434426. PharmX Technologies's gross margin of last year was 0.80977339. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Jun24)
=7.32/29.857
=0.24516864

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Jun23)
=6.487/36.52
=0.1776287

PharmX Technologies's asset turnover of this year was 0.24516864. PharmX Technologies's asset turnover of last year was 0.1776287. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+0+0+1+0+1+1
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

PharmX Technologies has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 4 mean?
PharmX Technologies (ASX:PHX) has a Piotroski F-Score of 4 as of Jun. 26, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on PharmX Technologies and its competitors. This is 20% below median its historical median of 5.00. Over the past decade, PharmX Technologies' Piotroski F-Score has ranged from 3.00 to 7.00. According to the industry distribution chart, PharmX Technologies ranks #439 out of 652 companies in the Healthcare Providers & Services industry, placing it in the top 67.3%.
Is PharmX Technologies' Piotroski F-Score too high?
PharmX Technologies' current Piotroski F-Score of 4 is 20% below median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 7.00. The Healthcare Providers & Services industry median Piotroski F-Score is 5.00. PharmX Technologies' value of 4 is 20% below this industry median. Based on the distribution chart, PharmX Technologies ranks #439 out of 652 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, PharmX Technologies has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PharmX Technologies' Piotroski F-Score compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, PharmX Technologies ranks #439 out of 652 companies for Piotroski F-Score. This places PharmX Technologies in the lower half of its industry. The industry median Piotroski F-Score is 5.00. PharmX Technologies' value of 4 is 20% below this benchmark. Historically, PharmX Technologies' own Piotroski F-Score has ranged from 3.00 to 7.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 5.00, PharmX Technologies has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Healthcare Providers & Services company?
The median Piotroski F-Score among Healthcare Providers & Services companies is 5.00, based on 652 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PharmX Technologies's current Piotroski F-Score of 4 is 20% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on PharmX Technologies and its competitors. For the Healthcare Providers & Services industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PharmX Technologies's current Piotroski F-Score is 4, which is 20% below median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmX Technologies stock overvalued right now?
Based on GuruFocus' analysis, PharmX Technologies (ASX:PHX) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.07, compared to a current price of A$0.13 — trading 85.7% above its estimated fair value. The current Piotroski F-Score is 4, which is 20% below median its 10-year median of 5.00 and 20% below the Healthcare Providers & Services industry median of 5.00. PharmX Technologies' overall GF Score™ is 40/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For PharmX Technologies (ASX:PHX), the current Piotroski F-Score is 4 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PharmX Technologies (ASX:PHX) Overvalued in 2026?

Based on GuruFocus' analysis, PharmX Technologies stock appears to be overvalued. The current stock price of A$0.13 is trading 85.7% above its estimated GF Value™ of A$0.07. GuruFocus considers PharmX Technologies to be Significantly Overvalued.

Key valuation signals for ASX:PHX:

  • Piotroski F-Score: 4 (20% below median its 10-year median of 5.00)
  • GF Value™: A$0.07 vs. price of A$0.13 (85.7% above fair value)
  • GF Score™: 40/100 with 3 warning signs
  • Industry Position: 20% below the Healthcare Providers & Services median (#439 of 652)

No single metric tells the full story. See the ASX:PHX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


PharmX Technologies Business Description

Address 17 Castlereagh Street, Suite 11.02, Level 11, Sydney, NSW, AUS, 2000
PharmX Technologies Ltd is an Australia-based software and technology company. The company has a single segment which is Health Services. In Health services, the company develops and distributes business software for the pharmacy industry with particular emphasis on point-of-sale and pharmaceutical dispensing software, support services, and associated computer hardware. It derives a majority of its revenue from the Health services business.
40GF Score

Get the complete analysis for ASX:PHX

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.13
Price
A$0.07
GF Value